TABLE 2.

The effects of concurrently administered systemic amikacin on e-bandage treatment efficacy^a

	Log10 CFU/g			ΔPurulence score			% Wound closure
	-−AMK	+ AMK		− AMK	+ AMK		−AMK	+ AMK
Tegaderm only	9.78	7.83	**c	+0.5	−1.14	NS	0.86%	23.13%	NS
Non-polarized e-bandage	8.97	8.11	*b	−1.0	−2.5	NS	26.83%	14.80%	NS
Polarized e-bandage	7.71	7.29	NS	−2.55	−3.14	NS	39.79%	12.15%	NS

^a Values represent means (N ≥ 8). Statistical analysis was performed using the Wilcoxon rank sum test. AMK = amikacin. NS = not significant.

^b P ≤ 0.05.

^c P ≤ 0.01.